TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia: A 13-week Randomized, Placebo Controlled Cross Over Trial
Brief Summary: This study was designed to investigate whether milnacipran is safe and effective in improving cognitive function in fibromyalgia. In addition, this study was aimed to investigate whether improvement in neurocognitive status due to milnacipran correlates with improvements in pain, to investigate whether improvement in neurocognitive status due to milnacipran correlates with improvements in fatigue, and to determine whether treatment with improvement in neurocognitive status, pain and fatigue correlates with functional improvement.


Options:
A: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Placebo (for Duloxetine); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Duloxetine) | Arm Label: Remifentanil; Type: EXPERIMENTAL; Interventions: Drug: Remifentanil | Arm Label: Placebo (for Remifentanil); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Remifentanil) | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Remifentanil; Assigned to Arm(s): Remifentanil | Intervention Type: DRUG; Name: Placebo (for Remifentanil); Assigned to Arm(s): Placebo (for Remifentanil) | Intervention Type: DRUG; Name: Placebo (for Duloxetine); Assigned to Arm(s): Placebo (for Duloxetine)
B: Arm Label: CBT and milnacipran; Type: EXPERIMENTAL; Interventions: Other: CBT and milnacipran | Arm Label: CBT and placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: CBT with a placebo | Arm Label: Educational with milnacipran; Type: ACTIVE_COMPARATOR; Interventions: Drug: Educational with milnacipran | Intervention Type: OTHER; Name: CBT and milnacipran; Assigned to Arm(s): CBT and milnacipran | Intervention Type: BEHAVIORAL; Name: CBT with a placebo; Assigned to Arm(s): CBT and placebo | Intervention Type: DRUG; Name: Educational with milnacipran; Assigned to Arm(s): Educational with milnacipran
C: Arm Label: milnacipran; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): milnacipran | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
D: Arm Label: Milnacipran; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Milnacipran, Drug: Placebo | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): Milnacipran, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Milnacipran, Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Milnacipran and Neurocognition, Pain and Fatigue in Fibromyalgia: A 13-week Randomized, Placebo Controlled Cross Over Trial
Brief Summary: This study was designed to investigate whether milnacipran is safe and effective in improving cognitive function in fibromyalgia. In addition, this study was aimed to investigate whether improvement in neurocognitive status due to milnacipran correlates with improvements in pain, to investigate whether improvement in neurocognitive status due to milnacipran correlates with improvements in fatigue, and to determine whether treatment with improvement in neurocognitive status, pain and fatigue correlates with functional improvement.


Options:
A: Arm Label: Minalcipran 100 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Arm Label: Minalcipran 150 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Arm Label: Minalcipran 200 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Intervention Type: DRUG; Name: milnacipran; Assigned to Arm(s): Minalcipran 100 mg, Minalcipran 150 mg, Minalcipran 200 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Minalcipran 100 mg, Minalcipran 150 mg, Minalcipran 200 mg
B: Arm Label: CBT and milnacipran; Type: EXPERIMENTAL; Interventions: Other: CBT and milnacipran | Arm Label: CBT and placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: CBT with a placebo | Arm Label: Educational with milnacipran; Type: ACTIVE_COMPARATOR; Interventions: Drug: Educational with milnacipran | Intervention Type: OTHER; Name: CBT and milnacipran; Assigned to Arm(s): CBT and milnacipran | Intervention Type: BEHAVIORAL; Name: CBT with a placebo; Assigned to Arm(s): CBT and placebo | Intervention Type: DRUG; Name: Educational with milnacipran; Assigned to Arm(s): Educational with milnacipran
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): 2
D: Arm Label: Milnacipran; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran, Drug: Placebo | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Milnacipran, Drug: Placebo | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): Milnacipran, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Milnacipran, Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial
Brief Summary: In the First-line Antimetabolites as Steroid-sparing Treatment (FAST) Uveitis Trial, the investigators propose to establish which immunosuppressive therapy, methotrexate or mycophenolate mofetil, is more effective as a first-line, corticosteroid-sparing agent for the treatment of non-infectious uveitis in a block-randomized, observer-masked, comparative effectiveness trial.


Options:
A: Arm Label: AIN457 300mg s.c weekly for 3 weeks; Type: EXPERIMENTAL; Interventions: Biological: AIN457 | Arm Label: AIN457 300mg s.c at baseline and Week 2; Type: EXPERIMENTAL; Interventions: Biological: AIN457 | Arm Label: AIN457 150mg s.c at baseline and Week 2; Type: EXPERIMENTAL; Interventions: Biological: AIN457 | Arm Label: Placebo s.c weekly for 3 weeks; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: AIN457; Assigned to Arm(s): AIN457 300mg s.c weekly for 3 weeks | Intervention Type: BIOLOGICAL; Name: AIN457; Assigned to Arm(s): AIN457 300mg s.c at baseline and Week 2 | Intervention Type: BIOLOGICAL; Name: AIN457; Assigned to Arm(s): AIN457 150mg s.c at baseline and Week 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo s.c weekly for 3 weeks
B: Arm Label: Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methotrexate | Arm Label: Mycophenolate mofetil; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mycophenolate mofetil | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Mycophenolate mofetil; Assigned to Arm(s): Mycophenolate mofetil
C: Arm Label: AIN457 300mg s.c every 2 weeks; Type: EXPERIMENTAL; Interventions: Drug: AIN457 | Arm Label: AIN457 300mg s.c. every 4 weeks; Type: EXPERIMENTAL; Interventions: Drug: AIN457 | Arm Label: AIN457 150mg s.c every 4 weeks; Type: EXPERIMENTAL; Interventions: Drug: AIN457 | Arm Label: Placebo s.c every 2 weeks; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AIN457; Assigned to Arm(s): AIN457 300mg s.c every 2 weeks | Intervention Type: DRUG; Name: AIN457; Assigned to Arm(s): AIN457 150mg s.c every 4 weeks | Intervention Type: DRUG; Name: AIN457; Assigned to Arm(s): AIN457 300mg s.c. every 4 weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo s.c every 2 weeks
D: Arm Label: Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate, Drug: Prednisone | Arm Label: Mycophenolate Mofetil; Type: EXPERIMENTAL; Interventions: Drug: Mycophenolate mofetil, Drug: Prednisone | Intervention Type: DRUG; Name: Mycophenolate mofetil; Assigned to Arm(s): Mycophenolate Mofetil | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Methotrexate | Intervention Type: DRUG; Name: Prednisone; Assigned to Arm(s): Methotrexate, Mycophenolate Mofetil

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Protocol for Brain-Centered Therapy Versus Medication for Urgency Urinary Incontinence An RCT: Hypnotherapy Or Pharmacotherapy
Brief Summary: This study is randomized controlled trial in which urgency incontinent women (approximately 150-160) will be randomized to hypnotherapy or pharmacotherapy and evaluated at months 2, 6 \&12 Hypotheses: Among patients with urgency urinary incontinence (UUI), hypnotherapy will be non-inferior pharmacotherapy in diminishing UUI episodes. Hypnotherapy may be superior or may not differ from pharmacotherapy in diminishing symptoms or quality of life based on validated questionnaires and/or other diary parameters.


Options:
A: Arm Label: Anticholinergic medications; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anticholinergic medications | Arm Label: Hypnotherapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Hypnotherapy | Intervention Type: DRUG; Name: Anticholinergic medications; Assigned to Arm(s): Anticholinergic medications | Intervention Type: BEHAVIORAL; Name: Hypnotherapy; Assigned to Arm(s): Hypnotherapy
B: Arm Label: Intravaginal Pessary; Type: EXPERIMENTAL; Interventions: Device: Intravaginal Pessary | Arm Label: Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Therapy | Arm Label: Pessary combined with behavioral therapy; Type: EXPERIMENTAL; Interventions: Device: Pessary combined with behavioral therapy | Intervention Type: BEHAVIORAL; Name: Behavioral Therapy; Assigned to Arm(s): Behavioral Therapy | Intervention Type: DEVICE; Name: Intravaginal Pessary; Assigned to Arm(s): Intravaginal Pessary | Intervention Type: DEVICE; Name: Pessary combined with behavioral therapy; Assigned to Arm(s): Pessary combined with behavioral therapy
C: Arm Label: Group Bladder Training; Type: EXPERIMENTAL; Interventions: Other: Bladder Training | Arm Label: Group TMAP; Type: ACTIVE_COMPARATOR; Interventions: Other: TMAP | Arm Label: Group Bladder Training + TMAP; Type: ACTIVE_COMPARATOR; Interventions: Other: Bladder Training + TMAP | Intervention Type: OTHER; Name: Bladder Training; Assigned to Arm(s): Group Bladder Training | Intervention Type: OTHER; Name: TMAP; Assigned to Arm(s): Group TMAP | Intervention Type: OTHER; Name: Bladder Training + TMAP; Assigned to Arm(s): Group Bladder Training + TMAP
D: Arm Label: Behavioral Training; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral training | Arm Label: Drug Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxybutynin chloride, extended-release | Intervention Type: BEHAVIORAL; Name: Behavioral training; Assigned to Arm(s): Behavioral Training | Intervention Type: DRUG; Name: Oxybutynin chloride, extended-release; Assigned to Arm(s): Drug Therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Protocol for Brain-Centered Therapy Versus Medication for Urgency Urinary Incontinence An RCT: Hypnotherapy Or Pharmacotherapy
Brief Summary: This study is randomized controlled trial in which urgency incontinent women (approximately 150-160) will be randomized to hypnotherapy or pharmacotherapy and evaluated at months 2, 6 \&12 Hypotheses: Among patients with urgency urinary incontinence (UUI), hypnotherapy will be non-inferior pharmacotherapy in diminishing UUI episodes. Hypnotherapy may be superior or may not differ from pharmacotherapy in diminishing symptoms or quality of life based on validated questionnaires and/or other diary parameters.


Options:
A: Arm Label: Oxybutynin topical gel; Type: EXPERIMENTAL; Interventions: Drug: Oxybutynin topical gel | Arm Label: Placebo topical gel; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo topical gel | Intervention Type: DRUG; Name: Oxybutynin topical gel; Assigned to Arm(s): Oxybutynin topical gel | Intervention Type: OTHER; Name: Placebo topical gel; Assigned to Arm(s): Placebo topical gel
B: Arm Label: Anticholinergic medications; Type: ACTIVE_COMPARATOR; Interventions: Drug: Anticholinergic medications | Arm Label: Hypnotherapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Hypnotherapy | Intervention Type: DRUG; Name: Anticholinergic medications; Assigned to Arm(s): Anticholinergic medications | Intervention Type: BEHAVIORAL; Name: Hypnotherapy; Assigned to Arm(s): Hypnotherapy
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: DR-3001a | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: DR-3001b | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: DR-3001a; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: DR-3001b; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 3
D: Intervention Type: DRUG; Name: tolterodine SR, overactive bladder; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact Evaluation of a Parenting Program to Improve Parenting, Education, and Health Outcomes for Young Children in Liberia
Brief Summary: The aim of this study is to assess the impact of an intervention to improve parenting practices, pre-academic and developmental skills, and use of mosquito nets for children in kindergarten in Liberia. A rigorous impact evaluation using a randomized, waitlist controlled design will be conducted to measure the impact of the intervention on three primary outcomes: positive parenting skills, children's cognitive and educational skills, and malaria knowledge and prevention behaviors.


Options:
A: Arm Label: Sinovuyo Caring Families Programme; Type: EXPERIMENTAL; Interventions: Behavioral: Sinovuyo Caring Families Programme | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Sinovuyo Caring Families Programme; Assigned to Arm(s): Sinovuyo Caring Families Programme
B: Arm Label: OHP and Treatment as usual (TAU); Type: EXPERIMENTAL; Interventions: Behavioral: Optimal Health Program, Other: Treatment as Usual | Arm Label: TAU Alone; Type: OTHER; Interventions: Other: Treatment as Usual | Intervention Type: BEHAVIORAL; Name: Optimal Health Program; Assigned to Arm(s): OHP and Treatment as usual (TAU) | Intervention Type: OTHER; Name: Treatment as Usual; Assigned to Arm(s): OHP and Treatment as usual (TAU), TAU Alone
C: Arm Label: "Parents Make the Difference"; Type: EXPERIMENTAL; Interventions: Behavioral: Parents Make the Difference | Arm Label: Waitlist Control; Type: OTHER; Interventions: Behavioral: Parents Make the Difference | Intervention Type: BEHAVIORAL; Name: Parents Make the Difference; Assigned to Arm(s): "Parents Make the Difference", Waitlist Control
D: Arm Label: Collaborative Stepped Care; Type: EXPERIMENTAL; Interventions: Other: Collaborative Stepped Care Intervention | Arm Label: Enhanced Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Enhanced Usual Care | Intervention Type: OTHER; Name: Collaborative Stepped Care Intervention; Assigned to Arm(s): Collaborative Stepped Care | Intervention Type: OTHER; Name: Enhanced Usual Care; Assigned to Arm(s): Enhanced Usual Care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: HIGH Altitude CArdiovascular REsearch in the ANDES
Brief Summary: This study is aimed to assess the efficacy of combined treatment with two antihypertensive agents (telmisartan and nifedipine) in subjects with mild hypertension exposed to high altitude.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Aminophylline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aminophylline | Arm Label: Methazolamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methazolamide | Arm Label: Aminophylline+Methazolamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aminophylline+Methazolamide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Aminophylline; Assigned to Arm(s): Aminophylline | Intervention Type: DRUG; Name: Methazolamide; Assigned to Arm(s): Methazolamide | Intervention Type: DRUG; Name: Aminophylline+Methazolamide; Assigned to Arm(s): Aminophylline+Methazolamide
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: ascent protocol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ascent protocol | Intervention Type: BEHAVIORAL; Name: ascent protocol; Assigned to Arm(s): 1, 2
C: Arm Label: Telmisartan/nifedipine; Type: EXPERIMENTAL; Interventions: Drug: Telmisartan, Drug: Nifedipine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): Telmisartan/nifedipine | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Telmisartan/nifedipine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Acetazolamide; Type: EXPERIMENTAL; Interventions: Drug: Acetazolamide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lactose monohydrate | Intervention Type: DRUG; Name: Acetazolamide; Assigned to Arm(s): Acetazolamide | Intervention Type: DRUG; Name: Lactose monohydrate; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: HIGH Altitude CArdiovascular REsearch in the ANDES
Brief Summary: This study is aimed to assess the efficacy of combined treatment with two antihypertensive agents (telmisartan and nifedipine) in subjects with mild hypertension exposed to high altitude.


Options:
A: Arm Label: Ibuprofen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ibuprofen | Arm Label: acetazolamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Acetazolamide | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Ibuprofen | Intervention Type: DRUG; Name: Acetazolamide; Assigned to Arm(s): acetazolamide
B: Arm Label: Telmisartan/nifedipine; Type: EXPERIMENTAL; Interventions: Drug: Telmisartan, Drug: Nifedipine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): Telmisartan/nifedipine | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Telmisartan/nifedipine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Aminophylline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aminophylline | Arm Label: Methazolamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methazolamide | Arm Label: Aminophylline+Methazolamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aminophylline+Methazolamide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Aminophylline; Assigned to Arm(s): Aminophylline | Intervention Type: DRUG; Name: Methazolamide; Assigned to Arm(s): Methazolamide | Intervention Type: DRUG; Name: Aminophylline+Methazolamide; Assigned to Arm(s): Aminophylline+Methazolamide
D: Arm Label: Erythropoietin; Type: EXPERIMENTAL; Interventions: Drug: Erythropoietin | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Erythropoietin; Assigned to Arm(s): Erythropoietin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: HIGH Altitude CArdiovascular REsearch in the ANDES
Brief Summary: This study is aimed to assess the efficacy of combined treatment with two antihypertensive agents (telmisartan and nifedipine) in subjects with mild hypertension exposed to high altitude.


Options:
A: Intervention Type: DRUG; Name: dexamethasone 8 mg bid; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tadalafil 10mg bid; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: ascent protocol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ascent protocol | Intervention Type: BEHAVIORAL; Name: ascent protocol; Assigned to Arm(s): 1, 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Sildenafil citrate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sildenafil citrate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Telmisartan/nifedipine; Type: EXPERIMENTAL; Interventions: Drug: Telmisartan, Drug: Nifedipine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): Telmisartan/nifedipine | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Telmisartan/nifedipine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Feasibility and Impact of an Evidence-based Electronic Decision Support System on Diabetes Care in Family Medicine: a Cluster Randomized Controlled Trial
Brief Summary: The purpose of this study is to assess the feasibility of the use of an evidence-based decision support system (EBMeDS) in daily Belgian family medicine and to study the effectiveness of EBMeDS use on improving diabetes care.


Options:
A: Arm Label: 1; Type: OTHER; Interventions: Drug: Insulin glulisine, Drug: Insulin glargine, Drug: Metformin | Arm Label: 2; Type: OTHER; Interventions: Drug: Insulin glulisine, Drug: Insulin glargine, Drug: Metformin | Intervention Type: DRUG; Name: Insulin glulisine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Insulin glargine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): 1, 2
B: Arm Label: Telemedical Coaching; Type: EXPERIMENTAL; Interventions: Behavioral: Telemedical coaching, Other: Telemedicine | Arm Label: Telemedicine; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telemedical coaching | Intervention Type: BEHAVIORAL; Name: Telemedical coaching; Assigned to Arm(s): Telemedical Coaching, Telemedicine | Intervention Type: OTHER; Name: Telemedicine; Assigned to Arm(s): Telemedical Coaching
C: Arm Label: EBMeDS group; Type: EXPERIMENTAL; Interventions: Behavioral: The EBMeDS system, Other: Evidence Linker | Arm Label: Control group; Type: OTHER; Interventions: Other: Evidence Linker | Intervention Type: BEHAVIORAL; Name: The EBMeDS system; Assigned to Arm(s): EBMeDS group | Intervention Type: OTHER; Name: Evidence Linker; Assigned to Arm(s): Control group, EBMeDS group
D: Arm Label: Technology-based self-management model; Type: EXPERIMENTAL; Interventions: Device: Technology-based self-management model | Arm Label: Conventional self-management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Technology-based self-management model; Assigned to Arm(s): Technology-based self-management model

Answer: C